Completing their strategic alliance in November 2008 to form the hybrid business model, Daiichi Sankyo and Ranbaxy have been moving forward to fully leverage the model.
In addition to meeting unmet medical needs through the development and marketing of new drugs, the group also operates an OTC business, and is accelerating its efforts to reinforce its vaccine business.
Leveraging Ranbaxy’s strengths, Daiichi Sankyo Espha will expand its product pipeline and continuously realize stable supply.
Takashi Shoda, president and CEO of Daiichi Sankyo, said: “Daiichi Sankyo is dedicated to meeting the universal desire of patients to improve their health and better balance their lives. We believe that our understanding of the Japanese market and local presence united with the global expertise of Ranbaxy in the generic arena will enable us to achieve efficient and immediate entry into the generic market.”
Atul Sobti, CEO and managing director of Ranbaxy, said: “Daiichi Sankyo’s leadership in the Japanese pharmaceutical market will guide us to further expand our business in Japan. Ranbaxy is committed to bringing high quality, affordable medicines to doctors and patients across the world.”